Chlamydia pneumoniae and coronary heart disease

Annals of Pharmacotherapy

Volumn 33, Issue 5, 1999, Pages 615-622

  Carlisle, Steven S ^a,b   Nahata, Milap C ^b  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^b NONE

Author keywords

Azithromycin; Chlamydia pneumoniae; Coronary artery disease; Roxithromycin

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; MACROLIDE; ROXITHROMYCIN;

ANIMAL MODEL; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

ANIMALS; ANTI-BACTERIAL AGENTS; ARTERIOSCLEROSIS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIALS; COMORBIDITY; CORONARY DISEASE; DATA COLLECTION; HUMANS;

EID: 0033060273     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18169     Document Type: Review

References (74)

1. Cook PJ, Lip GYH. Infectious agents and atherosclerotic vascular disease. Q J Med 1996;89:727-35.
2. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angio-graphically demonstrated coronary artery disease. JAMA 1992;268:68-72.
3. Osler W. Diseases of the arteries, In: Osler W, ed. Modem medicine: its practice and theory. Philadelphia: Lea and Febiger, 1908:429-47.
4. Burch GE, Harb JM, Hiramoto Y, Shewey L. Viral infection of the aorta of man associated with early atherosclerotic changes. Am Heart J 1973; 86:523-34.
5. Nicholls AC, Thomas M. Coxsackie virus infection in acute myocardial infarction. Lancet 1977;1:883-4.
6. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6.
7. Lowry RW, Adam E, Hu C, Kleiman NS, Cocanougher B, Windsor T, et al. What are the implications of cardiac infection with cytomegalovirus before heart transplantation? J Heart Lung Transplant 1994;13:122-8.
8. Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A 1983;80:6386-9.
9. Gyorkey F, Melnick JL, Guinn GA, Gyorkey P, DeBakey ME. Herpes-viridae in the endothelial and smooth muscle cells of the proximal aorta in arteriosclerotic patients. Exp Mol Pathol 1984;40:328-31.
10. Matilla KJ, Valle MS, Nieminen MS, Valtonen VV, Hietaniemi KL. Dental infections and coronary atherosclerosis. Atherosclerosis 1993; 103:205-11.
11. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311:711-4.
12. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437-9.
13. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, et al. Chronic Chlamydia pneunoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med 1992;116:273-8.
14. Saikku P. Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. Eur Heart J 1993;14(suppl):62-5.
15. Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, et al. Chlamydia pneumoniae strain TWAR antibody and angio-graphically demonstrated coronary artery disease. Arteriosclerosis Thromb 1991;11:547-51.
16. Kuo CC, Shor A, Campbell LA, Fukushi A, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-9.
17. Wang SP, Grayston JT. Population prevalence of antibody to Chlamydia pneumoniae strain TWAR. In: Bowie WR, Stamm WE, Ward ME, Ridgway GL, Schachter J, Caldwell HD, et al., eds. Chlamydial infections. Cambridge: Cambridge University Press, 1990:402-5.
18. Bierman EL. Atherosclerosis and other forms of arteriosclerosis. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 1994:1105-16.
19. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986;314:488-500.
20. Fernandopulle R, Loscalzo J. Atherosclerosis. In: Lilly LS, ed. Pathophysiology of heart disease. Philadelphia: Lea and Febiger, 1993:84-97.
21. Betzholtz C, Johnson A, Helden CH, Westermark B, Lind P, Urdea MS, et al. c-DNA and chromosomal localization of human platelet derived growth factor A-gene and its expression in tumor cell lines. Nature 1986;320:695-9.
22. Minick CR, Fabricant CG, Fabricant J, Litrena MM. Atherosclerosis induced by infection with a herpes virus. Am J Pathol 1979;96:673-706.
23. Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, Grant AJ. Herpes simplex virus infection in human arterial cells: implications in atherosclerosis. J Clin Invest 1987;80:1317-21.
24. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gombrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci U S A 1986;83: 4533-7.
25. Vallance P, Collier J, Bhagat K. Infection, inflammation and infarction: does acute endothelial cell dysfunction provide a link? Lancet 1997;349: 1391-2.
26. Mehta JL, Saldeen TG, Rand K. Interactive role of infection, inflammation, and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998;31:1217-25.
27. Fabricant CG, Fabricant J, Litrena MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978;48:335-40.
28. Fabricant CG, Fabricant J, Litrena MM, Minick CR. Herpesvirus-induced atherosclerosis in chickens. Fed Proc 1983;42:2476-9.
29. Garg R, Madans JH, Kleinman JC. Regional variation in ischemic heart disease. J Clin Epidemiol 1992;45:149-56.
30. Hahn DL. Regional variation in ischemic heart disease: a possible missing risk factor? J Clin Epidemiol 1993;46:668-9.
31. Ellis RW. Infection and coronary heart disease. J Med Microbiol 1997; 46:535-9.
32. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
33. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-5.
34. Patel P, Carrington D, Strachan DP, Leatham E, Goggin P, Northfield TC, et al. Fibrinogen: a link between chronic infection and coronary heart disease. Lancet 1994;343:1634-5.
35. Fowkes FGR, Lowe GDO, Houseley E, Rattray A, Rumley A, Elton RA, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease and risk of coronary heart disease. Lancet 1993; 342:84-6.
36. Tewari A, Buhles WC, Starnes HF. Preliminary report: effects of interleukin-1 in platelet counts. Lancet 1990;936:712-4.
37. Ritchy DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasma-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci U S A 1982;79:1530-4.
38. Van Lenten BJ, Fogerlman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A 1986;83:2704-8.
39. Lopes-Virell MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 1994;14(suppl K):118-24.
40. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumour necrosis factor. Proc Natl Acad Sci U S A 1985;82:8667-71.
41. Miettinen H, Lehto S, Saikku P, Haffner SM, Ronnemaa T, Pyorala K. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetics and non-diabetic subjects in Finland. Eur Heart J 1996;17: 682-8.
42. Ossewaarde JM, Vallinga C, Feskens EJM, Kromhout D. Infection with Chlamydia pneumoniae as a risk factor for coronary heart disease (the Zuthpen elderly study) (abstract). Atherosclerosis 1995;115(suppl):41.
43. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang SP, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med 1993;95:499-504.
44. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
45. Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993; 87:1130-4.
46. Ramirez JA, Ahkee S, Summersgill JT, Ganzel BL, Ogden LL, Quinn TC, et al. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996;125: 979-82.
47. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995;30:121-8.
48. Weiss SM, Roblin PM, Gaydos CA, Cummings P, Patton DL, Schulhoff N, et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996;173:957-62.
49. Aceti A, Mazzacurati G, Amendolea MA, Pennica A, Zechini B, Trappolini M, et al. H. pylori and C. pneumoniae infections may account for most acute coronary syndromes. BMJ 1996;313:428-9.
50. Juvonen J, Laurila A, Juvonen T, Alakarppa H, Surcel HM, Lounatmaa K, et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1997;29:1054-9.
51. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thompson MJ, Karagounis LA, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerosis versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555-61.
52. Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997;150:1785-90.
53. Dahlen DH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995;114: 165-74.
54. Cook PJ, Lip GYH, Wise R. Chlamydia pneumoniae and acute arterial thrombotic disease. Circulation 1995;92:3148-9.
55. Maas M, Bartels C, Engel P, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998;31:827-32.
56. Granfors K. Measurement of immunoglobulin M (IgM), IgG and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunoabsorbent assay: persistence of serum antibodies during disease. J Clin Microbiol 1979;9:336-41.
57. Hoiby N, Doring G. Immunoglobulin responses and immune complex formation in chronic lung diseases. Clin Microbiol News 1988;9:133-6.
58. Brett MM, Ghoneim AT, Littlewood JM. Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child 1990;65: 259-63.
59. Sarov I, Sarov B, Lunefeld E, Hagai Z, Chaim W, Figura B. The significance of Chlamydia-specific serum IgA antibodies in Chlamydia trachomatis infections. First Proceedings of the European Society of Chlamydia Research. Stockholm: Almqvist and Wiksell Int., 1988:234-8.
60. Chaim W, Sarov B, Sarov I, Piura B, Cohen A, Insler V. Serum IgG and IgA antibodies to Chlamydia in ectopic pregnancies. Contraception 1989;40:59-71.
61. Patnode D, Wang SP, Grayston J. Persistence of Chlamydia pneumoniae, strain TWAR microimmunofluorescent antibody. In: Bowie WR, Stamm WE, Ward ME, Ridgway GL, Schachter J, Caldwell HD, et al., eds. Chlamydial infections. Cambridge: Cambridge University Press, 1990:406-9.
62. Anderson P, Pederson OF, Bach B, Bonde GL. Serum antibodies and immunoglobulins in smokers and nonsmokers. Clin Exp Immunol 1982; 47:467-73.
63. Mili F, Flanders WD, Boring JR, Annest JL, Destefano F. The associations of race, cigarette smoking and smoking cessation to measures of the immune system in middle-aged men. Clin Immunol Immunopath 1991;59:187-200.
64. Blake GH, Abell T, Stanley W. Cigarette smoking and upper respiratory tract infection among recruits in basic combat training. Ann Intern Med 1988;109:198-202.
65. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 1994;23:1315-21.
66. Hahn DL, Saikku P. Chlamydia, smoking and heart disease (letter). Ann Intern Med 1992;117:71.
67. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J 1993;14:(suppl K):57-61.
68. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996;64:1614-20.
69. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
70. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomized trial of roxithromycin in non-Q wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
71. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
72. Lip GYH, Beevers DG. Can we treat coronary artery disease with antibiotics? Lancet 1997;350:378-9.
73. Martin D, Bursil J, Qui MR. Breit SN, Campbell T. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet 1998; 351:1858-9.
74. Grayston JT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation 1998;97:1669-70.